Literature DB >> 29280021

Clinical features and neurosurgical treatment of trigonal cavernous malformations.

Chengjun Wang1,2,3,4, Meng Zhao1,2,3,4, Xiaofeng Deng1,2,3,4, Jia Wang1,2,3,4, Zhongli Jiang1,2,3,4, Jizong Zhao5,6,7,8.   

Abstract

The goals of this study were to analyze the incidence, clinical manifestations, neuroimaging findings, surgical treatments, and neurological outcomes of trigonal cavernous malformations (TCMs). Among 1395 cases of intracranial and intraspinal cavernous malformations (CMs) surgically treated between 2003 and 2016 at Beijing Tiantan Hospital, a series of 12 patients with TCM was chosen for analysis and their records were reviewed. We also performed an exhaustive literature search using PubMed to identify all previously reported cases in the literatures. TCMs accounted for 0.86% of the entire series of the central nervous system (CNS) CMs. The case series consisted of five male and seven female patients (ratio 1:1.4), with an average age at presentation of 32.9 years (7-53 years). In all the cases, headache was the most common initial symptom (66.7%). Complete resection without surgical mortality was achieved in all the cases. Postoperative complications included fever, lower limb weakness, sensory aphasia, and calculational capacity declination. Follow-up period after diagnosis was 15 to 74 months (mean 48.3 months); no patient was lost to follow-up. All the patients were considered to be in excellent clinical condition. TCMs are rare lesions; they can reach large size, and their symptoms and signs commonly resulted from mass effect. Surgical intervention is the treatment of choice for TCMs; patients can obtain favorable neurological outcomes after complete resection.

Entities:  

Keywords:  Cavernous malformation; Intraventricular tumor; Surgical treatment; Trigone

Mesh:

Year:  2017        PMID: 29280021     DOI: 10.1007/s10143-017-0938-5

Source DB:  PubMed          Journal:  Neurosurg Rev        ISSN: 0344-5607            Impact factor:   3.042


  46 in total

1.  Transcortical surgery for lateral ventricular tumors.

Authors:  R G Ellenbogen
Journal:  Neurosurg Focus       Date:  2001-06-15       Impact factor: 4.047

Review 2.  Cavernous angiomas of the lateral ventricles.

Authors:  Rodrigo Carrasco; Manuel Pedrosa; José M Pascual; Marta Navas; Ricardo Liberal; Rafael G Sola
Journal:  Acta Neurochir (Wien)       Date:  2009-02-05       Impact factor: 2.216

Review 3.  Intraventricular cavernous angioma. A survey.

Authors:  M Tatagiba; R Schönmayr; M Samii
Journal:  Acta Neurochir (Wien)       Date:  1991       Impact factor: 2.216

4.  Stereotactic radiosurgery for cavernous malformations: is it effective?

Authors:  Nohra Chalouhi; Pascal Jabbour; David W Andrews
Journal:  World Neurosurg       Date:  2012-10-27       Impact factor: 2.104

5.  Intraventricular cavernous hemangioma. Case report.

Authors:  H Iwasa; I Indei; F Sato
Journal:  J Neurosurg       Date:  1983-07       Impact factor: 5.115

6.  [Surgery of trigonal tumor].

Authors:  H Handa; S Nagasawa
Journal:  No Shinkei Geka       Date:  1984-07

Review 7.  From the archives of the AFIP. Cerebral intraventricular neoplasms: radiologic-pathologic correlation.

Authors:  Kelly K Koeller; Glenn D Sandberg
Journal:  Radiographics       Date:  2002 Nov-Dec       Impact factor: 5.333

8.  Pterional surgery of meningiomas of the tuberculum sellae and planum sphenoidale: surgical results with special consideration of ophthalmological and endocrinological outcomes.

Authors:  Rudolf Fahlbusch; Werner Schott
Journal:  J Neurosurg       Date:  2002-02       Impact factor: 5.115

Review 9.  Trigonal cavernous angioma: a short illustrated review.

Authors:  L C Stavrinou; G Stranjalis; T Flaskas; D E Sakas
Journal:  Acta Neurochir (Wien)       Date:  2009-03-20       Impact factor: 2.216

10.  Health related quality of life measured by SF-36: a population-based study in Shanghai, China.

Authors:  Rui Wang; Cheng Wu; Yanfang Zhao; Xiaoyan Yan; Xiuqiang Ma; Meijing Wu; Wenbin Liu; Zheng Gu; June Zhao; Jia He
Journal:  BMC Public Health       Date:  2008-08-19       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.